Frank Rimerman Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Frank Rimerman Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$529K	Hold	1,802	–	–	0.03%	400
2026 Q1	$502K	Hold	1,802	–	–	0.03%	377
2025 Q4	$546K	Sell	1,802 -1	-0.1%	-$312	0.03%	360
2025 Q3	$506K	Sell	1,803 -3	-0.2%	-$816	0.03%	370
2025 Q2	$436K	Buy	1,806 +53	+3%	+$12.5K	0.03%	373
2025 Q1	$427K	Sell	1,753 -23	-1%	-$6.92K	0.03%	348
2024 Q4	$583K	Buy	1,776 +5	+0.3%	+$1.7K	0.04%	273
2024 Q3	$593K	Sell	1,771 -277	-14%	-$88K	0.04%	299
2024 Q2	$559K	Buy	+2,048	New	+$596K	0.04%	315

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Frank Rimerman Advisors's BIO Position: Q2 2026 in Review

Frank Rimerman Advisors held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 1,802 shares worth $529K. The position accounts for 0.03% of the portfolio, ranked #400.

Frank Rimerman Advisors first reported a position in BIO in Q2 2024 and has held it in 9 quarters since. The position peaked at $593K in Q3 2024. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Frank Rimerman Advisors held 1,802 shares of Bio-Rad Laboratories Class A worth $529K as of Q2 2026.
Frank Rimerman Advisors left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
Bio-Rad Laboratories Class A made up 0.03% of Frank Rimerman Advisors's portfolio in Q2 2026, its #400 holding.
Frank Rimerman Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2024 and has held it in 9 quarters since.
Frank Rimerman Advisors's Bio-Rad Laboratories Class A position peaked at $593K in Q3 2024.
399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.